Parkinson’s Disease in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson’s Disease market through 2033.
Across the 68 markets, sales in the Parkinson’s Disease market were $5.1 billion in 2023, growing to $10.1 billion in 2033.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 66.0% and 69.6% of 68-market sales in 2023 and 2033, respectively.
Scope
Overview of Parkinson’s Disease, including epidemiology, symptoms, diagnosis, and disease management.
Annualized Parkinson’s Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson’s therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson’s treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global Parkinson’s Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson’s Disease therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson’s Disease therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
NeuroDerm Ltd
USB Corp
Newron
Italfarmaco SpA
Kyowa Kirin Co Ltd
Acadia Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Sumitomo Pharma Co Ltd
Otsuka Pharmaceutical Co Ltd
Novartis AG
Eisai Co Ltd
Acorda Therapeutics Inc
Stada Arzneimittel AG
Meiji Co Ltd
Amneal Pharmaceuticals Inc
Alliance Pharma Plc
Britannia Pharmaceuticals Ltd
Annovis Bio Inc
US WorldMeds LLC
Hisamitsu Pharmaceutical Co Inc
Lundbeck LLC
Viatris
Supernus Pharmaceuticals Inc
AbbVie Inc
Prothena Corp Plc
Takeda (Pty) Ltd
Organon
Pharma Two B Ltd
Anavex Life Sciences Corp
Sunovion Pharmaceuticals Asia Pacific Pte Ltd
Meiji Seika Pharma Co Ltd
Alkahest Inc
Teva LLC
Glaxo Smith Kline (GSK)
HLS Therapeutics Inc
Roche
ADAMAS
IRLAB Therapeutics AB
Neuraly Inc
Taiyo Pharma Co Ltd
PureIMS BV
Alora Pharmaceuticals LLC
PharmaTher Holdings Ltd
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Parkinson's Disease reports